Aquilo Capital, L.P. 4
4 · Spero Therapeutics, Inc. · Filed Sep 26, 2022
Insider Transaction Report
Form 4
Aquilo Capital Management, LLC
10% Owner
Transactions
- Sale
Common Stock, $0.001 par value
2022-09-22$2.25/sh−1,335,512$3,005,303→ 3,985,719 total(indirect: See Footnotes) - Sale
Common Stock, $0.001 par value
2022-09-22$2.25/sh−566,284$1,274,309→ 3,419,435 total(indirect: See Footnotes)
Footnotes (3)
- [F1]The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein.
- [F2]Aquilo Capital, LP owns 2,176,470 of the 3,985,719 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP sold 1,335,512 shares in this transaction on 09/22/2022.
- [F3]Aquilo Capital, LP owns only 2,176,470 of the 3,419,435 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not sell any of the 566,284 shares sold in this transaction on 09/22/2022.